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http://www.biomedcentral.com/1471-2369/15/73RESEARCH ARTICLE Open AccessDevelopment of a questionnaire to evaluate
practitioners’ confidence and knowledge in
primary care in managing chronic kidney disease
Mohammad Tahir1,2*, Simon Hassan1,2, Simon de Lusignan1, Lazza Shaheen2, Tom Chan1 and Olga Dmitrieva1Abstract
Background: In the UK, chronic disease, including chronic kidney disease (CKD) is largely managed in primary care.
We developed a tool to assess practitioner confidence and knowledge in managing CKD compared to other
chronic diseases. This questionnaire was part of a cluster randomised quality improvement interventions in chronic
kidney disease (QICKD; ISRCTN56023731).
Methods: The questionnaire was developed by family physicians, primary care nurses, academics and renal
specialists. We conducted three focus groups (n = 7, 6, and 8) to refine the questionnaire using groups of general
practitioners, practice nurses and trainees in general practice. We used paper based versions to develop the
questionnaire and online surveys to test it. Practitioners in a group of volunteer, trial practices received the
questionnaire twice. We measured its reliability using Cohen’s Kappa (K).
Results: The practitioners in the focus groups reached a consensus as to the key elements to include in the
instrument. We achieved a 73.1% (n = 57/78) initial response rate for our questionnaire; of these 57, 54 completed
the questionnaire a second time. Family physicians made up the largest single group of respondents (47.4%,
n = 27). Initial response showed more female (64.9%, n = 37) than male (35.1%, n = 20) respondents. The reliability
results from retesting showed that there was moderate agreement (k > 0.4) on all questions; with many showing
substantial agreement (k > 0.6). There was substantial agreement in the questions about loop diuretics (k = 0.608,
CI 0.432-0.784, p < 0.001), confidence in managing hypertension (k = 0.628, 95%CI 0.452-0.804, p < 0.001), diastolic
blood pressure treatment thresholds in CKD (k = 0.608, 95%CI 0.436-0.780, p < 0.001) and the rate of decline of eGFR
that would prompt referral (k = 0.764, 95%CI 0.603-0.925, p < 0.001).
Conclusion: The QICKD-CCQ is a reliable instrument for measuring confidence and knowledge among primary care
practitioners on CKD management in the context of UK primary care.
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Quality of HealthcareBackground
The management of chronic kidney disease (CKD) is a
new challenge for primary care practitioners [1,2]. It in-
volves the risk stratification of patients by disease severity
using primary care data [3-5]. CKD has been included in
the range of guidelines published by the National Institute
for Health and Clinical Excellence (NICE) since 2008,* Correspondence: mtahir@nhs.net
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reproduction in any medium, provided the orprimary care clinicians are expected to implement these
[6]. These guidelines follow those of The National Kidney
Foundation Kidney Disease Outcomes Quality Initiative
(NKF KDOQI™) [7]. Additionally, in the UK, CKD man-
agement has been added to pay-for-performance (P4P)
targets for primary care. P4P was introduced for chronic
disease management in primary care in 2004, and ex-
tended to include CKD in 2006 [8]. Whilst the response
to P4P has been mixed [9-11], it is plausible that these
P4P interventions might impact on renal replacement
therapy, as P4P represents a form of quality improvementd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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[12,13]. When CKD was added to the quality indicators,
little was known about how to improve quality in this con-
dition [12]. The Quality Improvement in CKD trial
(QICKD) [14] included a systematic review [12] and diag-
nostic analysis [15] to explore factors limiting achievement
of quality improvement in CKD. This revealed that pri-
mary care practitioners had gaps in their knowledge,
highly variable views about this condition and lacked con-
fidence in explaining and managing the condition [15,16].
We are not aware of any questionnaires to measure
practitioner confidence and knowledge in the manage-
ment of CKD. Despite this, clear guidance does exist on
priority areas to address in patients with CKD, such as
systolic blood pressure and proteinuria [6,17,18]. Ques-
tionnaires provide a reliable way of measuring confidence
and knowledge if properly developed. We developed this
questionnaire as part of the process of evaluating of a
large cluster randomised trial: the QICKD trial [19]. The
QICKD has three arms: “Audit based education” (feed-
back of performance compared with peers in an educa-
tional context) [20]; “Guidelines and prompts” (postal
reminders about management of CKD and copies of
national guidance) [21]; and usual practice. This paper
reports how we developed and tested this questionnaire
to provide a reliable instrument to measure confidence
and knowledge in managing CKD. We would like this
questionnaire to be used as a tool to measure confidence
and knowledge in managing CKD with an emphasis on
managing blood pressure control in these patients.
Method
Literature review
We carried out a literature review [12], a diagnostic ana-
lysis [15] and these were summarised in the overall
protocol [19] to identify whether there were any existing
validated tools we could use for measuring confidence in
CKD. We particularly looked for tools developed for the
management of other cardiovascular diseases including
diabetes, as strict management of BP and of proteinuria
are key aspects of the primary care management of both
conditions. We also searched for other literature about
the validation of questionnaires to discover the typical
sample sizes used and expected response rate from test-
retest studies [22,23].
Developing a valid questionnaire
We agreed the key objective for the questionnaire was to
find out how confident and knowledgeable practitioners
were in managing the QICKD’s primary outcome meas-
ure: systolic blood pressure (SBP). As we could not make
absolute measures of confidence we decided to compare
confidence levels against other well established chronic
conditions managed in primary care. These chronicconditions were felt to be important and comparable by
our project group which consisted of general practi-
tioners, nurses and renal specialist. The questionnaire
content was further tested with the focus groups below.
The final objectives of our questionnaire were:
 To compare the confidence of practitioners in
controlling systolic BP in patients with CKD with
that in patients with hypertension alone. Improved
control of systolic BP is the primary outcome
measure of the QICKD [12].
 To compare confidence in managing proteinuria in
CKD with diabetes. Patients with CKD and
proteinuria are at high risk of adverse renal and
cardiovascular outcomes [17].
 To compare confidence levels in General Practitioner
(GP) partners, salaried GPs and nurses. Our
systematic review indicated that successful initiatives
in CKD had often been non-doctor led [12].
 To create a questionnaire that a busy primary care
practitioner, GP or nurse, could complete in a
maximum of 10 minutes.
 The focus groups also addressed the importance of
including confidence in initiating antihypertensive
therapy angiotensin converting enzyme inhibitors
(ACE-I) and angiotensin II receptor blockers (ARB)
according to guidelines.
The knowledge questions were about BP targets for
treatment, intervention levels of proteinuria and criteria
for referral. The questions asked for numeric responses
with respect to: BP management; change in renal func-
tion requiring referral (measured with an estimate of
glomerular filtration rate (eGFR)); quantitative measures
of proteinuria (in the UK measured using albumin cre-
atinine ratio (ACR)); and decline in renal function that
should result in referral to specialist care.
We used an established four stage method to develop
the confidence questionnaire: (1) Planning, (2) Piloting,
including response formats, (3) Layout finalisation and
question ordering, (4) Developing the covering letter/
distribution method [24]:
1. Planning
We developed a project plan for the development of
the questionnaires and appointed a project team
from within the QICKD study team. We developed
further objectives based on our study using
knowledge gained from our systematic review12 and
diagnostic analysis [15]. We planned to distribute the
questionnaire initially on paper, with the option of
follow-up questionnaires being completed online. The
additional areas in the project plan concerned the
resources required to complete the questionnaire.
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We circulated a draft questionnaire amongst the
investigators. We then held a group discussion to
identify current issues in CKD management, to
check the objectives developed in the planning
phase, and identify any new items. At these
meetings, we elected to include a small number of
key knowledge questions, as it was felt that
confidence could not be interpreted in complete
isolation. We defined the ‘confidence’ components as
what individuals know about their ability–in this
case based on the knowledge of guidelines, as well as
previous experience of the task. We selected
components in our questionnaire that we thought
would be appropriate surrogates to a broader level
of components. We used a ranking exercise to
prioritise the areas of knowledge to be tested. We
decided to restrict our knowledge test to key data
that had numeric responses. This draft questionnaire
was then piloted on practitioners. This cycle was
repeated on three occasions. We conducted three
focus groups (n = 7, 6, and 8) to refine the
questionnaire using groups of general practitioners,
practice nurses and trainees in general practice.
These focus groups were facilitated by AT, and
attendees were asked to comment on what they
thought should be the primary focus of the
questionnaires. The process involved the
practitioners completing the questionnaire and then
marking a colleague’s questionnaire while discussing
the responses and highlighting potential ambiguities.
We chose to “mark” each other so that we could
encourage an open discussion about the responses
given by our colleagues. The focus groups’
comments were captured using a field notebook, the
annotated questionnaires, flipchart notes capturing
the key findings and tape recording of two out of
three of the focus groups (one recording failed),
which were subsequently transcribed. A smaller
group of GPs was contacted via email (n = 3) to test
the feasibility of collecting data remotely [25]. We
reviewed our findings and found that we had
significantly increased the number of questions
during this process, and that we needed to
subsequently reduce them. We felt we needed to
keep the number to a manageable time limit of
around 5–10 minutes as this felt acceptable to the
participants and more likely to return a greater
response rate.
3. Layout finalisation and question ordering
We explored various layouts and arrangements of the
questionnaire with our focus group attendees and
then asked them to test the final version online. Focus
groups also suggested that we should give thequestionnaire a logical progression, mimicking the
traditional progression in medical management of a
condition. We therefore initially grouped questions
about history, investigation and diagnosis. The focus
groups found our initial ordering difficult with some
participants “flipping” the Likert scale. In other words
participants felt that ‘5’ should represent very
confident and ‘1’ not confident at all. We therefore
accepted their recommendations, and we added
shading and “smiley faces” ranging from confident
(happy) through to not-confident (sad). The final
questionnaire consisted of 24 confidence questions
and 6 knowledge questions (Additional file 1). The
confidence questions used a five item Likert scale,
where 1 is “Not confident at all” and 5 is “Very
confident.”
4. Developing the distribution method including the
covering letter
Each clinician received an email link to complete the
questionnaire (Survey Monkey Questionnaire™).
We prompted non-responders up to three times for
each collection. We used a combination of email
announcing the intention to telephone, followed up
by a phone call if there was no response. The
process was repeated, allowing a minimum of two
and no longer than five weeks between the test and
retest; to test rater-rater reliability. The participants
were not compensated for the time taken to do the
questionnaire.
Sampling frame for testing questionnaire reliability
We identified a sample of 78 practitioners, drawn from a
network of 13 practices: either in-depth process evalu-
ation practices or others were associated with the princi-
pal and a senior researcher to test the reliability of the
questionnaire. The geographical spread of these prac-
tices is in southern England and represent practices with
a registered list size ranging from 2600 up to 12000 pa-
tients. The in-depth process evaluation practices were a
group of practices in the QICKD trial which received
the same intervention as the main trial practices but
were also observed so we could learn about programme
fidelity (i.e. the extent to which the intervention ran as
planned) and intervention exposure (i.e. the extent to
which members of trial practices were exposed to the
intervention) [19,15]. We aimed to achieve 50 paired re-
sponses. Each clinician was required to complete the
questionnaire on two separate occasions between 2-5
weeks apart. We included paired responses and consid-
ered a valid response to be a questionnaire with more
than 80% of the responses included. Paired responses are
required to calculate a Cohen’s kappa. Paired question-
naires were only requested from those initially complet-
ing the questionnaire on the first collection sample. The
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and analysis; this was through the appointment of a re-
searcher to administer the questionnaire delivery. Any
surveys completed by telephone or on paper were input-
ted by a research assistant.
Statistical methods for testing reliability
Rater-rater reliability is a measure used to examine the
agreement between two ratings on the assignment of
categories of a categorical variable. It is an important
measure in determining how well the implementation
of a coding or measurement system works. We used
Cohen’s Kappa (K) as a statistical measure of rater-rater
reliability. The ranges of this coefficient are generally be-
tween 0 to 1.0 (although negative numbers are possible),
where large numbers mean better reliability and values
near or less than zero suggest that agreement is attribut-
able to chance alone [26]. We categorised the level of
agreement achieved using Cohen’s Kappa as follows:
Less than zero: poor agreement; 0.0-0.20: slight agree-
ment; 0.21-0.40: fair agreement; 0.41-0.60: moderate
agreement; 0.61-0.80: substantial agreement; 0.81-1.00:
almost perfect agreement. Where there was asymmetry
between test and retest answers, we collapsed the cat-
egories where there was no response so that we could
make a valid comparison.
Ethical considerations
This questionnaire development does not require ethical
approval, however the questionnaire will be used as part
of the QI-CKD study which was approved by the NationalFigure 1 First response to distribution of questionnaires for testing reResearch Ethics Service’s Oxford Research Ethics commit-
tee and is a registered clinical trial (ISRCTN56023731).
Results
Reliability testing
The response rate for the first questionnaire was 73.1%
(n = 57/78) valid questionnaires. There were no invalid
responses. Of the 57 primary care professionals (PCP)
who completed the first round 54 completed the second:
a 69.2% (n = 54/78) response rate providing 54 paired
questionnaires. Responses were received from all 13
practices taking part (Figure 1, Figure 2). We had 54
paired responses; however one 2nd round response had
incomplete data. We therefore were unable to compare
this data for the responses to the majority of the ques-
tions but we were able to identify the characteristics of
the respondent. Therefore for Cohen’s kappa calcula-
tions we used 53 paired responses.
General practitioners who are partners and salaried
GP’s made up the largest single group of respondents
(47.4%, n = 27) followed by nurses (28.1%, n = 16). Lo-
cums and trainees made up the smallest group of re-
spondents (Table 1).
There were more female respondents (64.9%, n = 37)
than male (35.1%, n = 20) (Table 2). More of the female
respondents of this sample are in the older age bands
and all the nurses are female (28.1%, n = 16). There was
an equal split between practitioners who work full and
part-time (49.1% vs. 50.9%). More female clinicians work
part-time than male clinicians. However, this finding is
not statistically significant.liability.
Table 1 Role and response rates
Roles Absolute
sent out
Completed
Round 1
Completed both
Rounds
GP 41 27 (47.4%) 25 (46.3%)
Locum GP 8 8 (14.0%) 8 (14.8%)
Trainee GP 6 6 (10.5%) 6 (11.1%)
Nurse 23 16 (28.1%) 15 (27.8%)
Total 78 57 (73.1% of sent out) 54 (69.2% of sent out)
Figure 2 Testing of second round of questionnaires
for reliability.
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calculate a Kappa coefficient for, with all but two ques-
tions having symmetry in the result. All the Kappa coef-
ficients for the confidence questions are within the
moderate to substantial range of agreement (K > 0.4) and
were statistically significant. There was substantial agree-
ment in the questions about loop diuretics (k = 0.608, 95%
CI 0.432-0.784, p < 0.001,) and confidence in managing
hypertension (k = 0.628, 95% CI 0.452-0.804, p < 0.001,).
Two pairs of ratings were asymmetrical, for example the
question about confidence with hypertension. This pair of
ratings was re-coded to three categories and Kappa statis-
tics calculated (Table 3).
Our knowledge questions showed Kappa coefficients
within the moderate to substantial range of agreement
and all were statistically significant. There was substantial
agreement for the questions about diastolic blood pressure
treatment in CKD without proteinuria (k = 0.608, 95% CI
0.436-0.780, p < 0.001,) and the rate of decline of eGFR
that would prompt referral to secondary care (k = 0.764,
95% CI 0.603-0.925, p < 0.001,) (Table 4).Table 2 Demographic status and response rate of the particip
Gender Age Band
25-34 35-44 45-54
Male 10 9 1
Female 12 7 13
Total 22 (38.6%) 16 (28.1%) 14 (24.6%)We attach a correlation matrix as an additional means
to assess how similar or dissimilar one question is to an-
other (Additional file 2).Discussion
Principal findings
The Clinician Confidence and Knowledge Questionnaire
(CCQ) appears to be a reliable instrument in testing
confidence and knowledge in the management of CKD,
hypertension and diabetes. There was consensus about
which items should be included in such a questionnaire,
and about the key areas of knowledge. The CCQ pro-
vides higher levels of reliability when testing knowledge
rather than confidence. The CCQ appears easy to
complete with nearly all volunteers completing the
paired questionnaires.Implications of the findings
The appropriateness of the questionnaire is framed by
the UK context and guidelines at the time the instru-
ment was created, though these do not vary substantially
from international trends in managing this condition.
However, whilst the knowledge questions may change
over time, comparing confidence with the management
of other chronic diseases in primary care is likely to re-
main a valid, albeit changing, comparison. The CCQ en-
ables a reliable measure of knowledge and confidence to
be assessed. It can be used as a tool to assess interven-
tions that might improve the confidence and knowledge
of primary care practitioners. If we accept the link
between confidence and knowledge this might enable
a measure of confidence as a proxy for improving
knowledge.ants
Employment Status Total
55-64 Full-time Part-time
0 12 8 20
5 17 20 37
5 (8.8%) 29 (50.9%) 28 (49.1%) 57 (100%)
Table 3 Cohen’s Kappa showing rater-rater reliability for confidence questions
Question stem–How confident are you at: Cohen’s Kappa SE Probability p 95% CI Count n
…managing hypertension as a disease? 0.458 0.113 p < 0.001 0.237 to 0.679 53
…managing hypertension in patients with CKD? 0.628 0.090 p < 0.001 0.452 to 0.804 53
…managing hypertension in patients with CKD with Diabetes? 0.562 0.095 p < 0.001 0.376 to 0.748 53
..that you can achieve lowered blood pressure in patients with CKD? 0.569 0.103 p < 0.001 0.367 to 0.771 53
…interpreting eGFR to stage CKD? 0.561 0.087 p < 0.001 0.39 to 0.732 53
..with monitoring eGFR in patients with CKD? 0.426 0.092 p < 0.001 0.246 to 0.606 53
…monitoring eGFR in CKD patient with Diabetes? 0.413 0.091 p < 0.001 0.235 to 0.591 53
…identifying significant proteinuria in patients with Diabetes? 0.495 0.097 p < 0.001 0.305 to 0.685 53
…identifying significant proteinuria in patients with CKD? 0.481 0.094 p < 0.001 0.297 to 0.665 52
…using urine protein (ACR or PCR) results to manage Diabetes? 0.421 0.093 p < 0.001 0.239 to 0.603 52
…using urine protein (ACR or PCR) results to manage CKD? 0.486 0.094 p < 0.001 0.302 to 0.67 51
…using ACE inhibitors and / or ARB’s? 0.589 0.094 p < 0.001 0.405 to 0.773 53
…using ACE inhibitors and / or ARB’s in patients with CKD? 0.591 0.089 p < 0.001 0.417 to 0.765 53
..using other anti-hypertensives in patients with CKD? 0.508 0.096 p < 0.001 0.32 to 0.696 53
…in adding a loop diuretic drug to patients with CKD (stage 3b and
above) already on maximum dose of an ACE inhibitor and/or ARB?
0.608 0.0896 p < 0.001 0.432 to 0.784 53
…identifying CVD risk factors for patients with CKD? 0.573 0.100 p < 0.001 0.377 to 0.769 53
…assessing CVD risk scores in patients with Diabetes? 0.539 0.097 p < 0.001 0.349 to 0.729 53
…assessing CVD risk scores in patients with CKD? 0.523 0.099 p < 0.001 0.329 to 0.717 53
…initiating therapy to lower lipid levels in patients with heart disease? 0.557 0.106 p < 0.001 0.349 to 0.765 53
…initiating therapy to lower lipid levels in patients with CKD? 0.603 0.091 p < 0.001 0.425 to 0.781 53
…using referral guidelines to refer appropriate patients with
Diabetes (Type 2) to secondary care?
0.489 0.095 p < 0.001 0.303 to 0.675 53
…using referral guidelines to refer appropriate patients with
CKD to secondary care?
0.558 0.086 p < 0.001 0.389 to 0.727 53
…the overall management of patients with Diabetes (Type 2)? 0.545 0.098 p < 0.001 0.353 to 0.737 53
…the overall management of patients with CKD? 0.543 0.091 p < 0.001 0.365 to 0.721 53
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Studies have shown a knowledge gap in CKD management
[27-29], reinforcing the findings of our own diagnostic ana-
lysis [15]. Further, a recent study of the use of laboratory
prompts shows that they alone are not sufficient to raise
the standard of care [30]. However, there are some pointers
from educational research and from other disease areasTable 4 Cohen’s Kappa showing rater-rater reliability for kno
Question–Stem: What level of…
At what level of eGFR would you typically refer to secondary care?
… SYSTOLIC blood pressure control do you typically aim to achieve in
patients with CKD WITHOUT proteinuria?
… DIASTOLIC blood pressure control do you typically aim to achieve in
patients with CKD WITHOUT proteinuria?
… SYSTOLIC blood pressure control do you typically aim to achieve in
patients with CKD WITH proteinuria?
… DIASTOLIC blood pressure control do you typically aim to achieve in
patients with CKD WITH proteinuria?
What rate of decline per annum in eGFR would prompt you to refer to secothat level of knowledge [31,32] and confidence is associated
with improved practice; however most of these articles are
descriptive rather than trial-based. A literature search on
questionnaires and reliability revealed very few articles as-
sociated with confidence; though a city-based collaborative
which also included education and better use of technology
appears to have improved care [33].wledge questions
Kappa SE p 95% CI n
0.551 0.098 p < 0.001 0.359 to 0.743 53
0.472 0.123 p < 0.001 0.230 to 0.713 53
0.608 0.088 p < 0.001 0.436 to 0.780 53
0.583 0.099 p < 0.001 0.389 to 0.777 53
0.482 0.100 p < 0.001 0.286 to 0.678 53
ndary care? 0.764 0.082 p < 0.001 0.603 to 0.925 53
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We received less than 80% for the initial response rate
(n = 57, 73.1%), however our paired response rate was
94.7% (n = 54/57). There may be a number of sources of
bias in this investigation. Firstly, the practices participat-
ing in this study are pre-selected by the researchers and
may not be representative of the wider population and
we do not report on non-responders. The study does
not compare confidence and knowledge to clinical out-
comes for patients, namely, their enablement [34] or
awareness of their diagnosis [35], and so cannot associ-
ate high scores with improved care. We also do not
measure competence because competence includes
knowledge, skills and attitudes [36]. It is possible that
treatment thresholds or the measures of renal function
or for testing proteinuria may vary between health sys-
tems; however these aspects of the questionnaire can be
adapted to keep abreast of a changing evidence base and
practice. For example, the use of total protein creatinine
ratio rather than albumin and creatinine ratio (ACR) as
a proteinuria test; or the use of another method of meas-
uring renal function.
Call for further research
We need to compare confidence and knowledge with
clinical outcomes in CKD [31]. Further studies of the
provision of educational or other interventions to people
who lack confidence in managing a condition should be
conducted to determine whether this improves the qual-
ity of care.
Conclusion
The CCQ instrument should be added to the armament-
arium of improvement tools and confidence measures in
primary care practitioners for the assessment of confi-
dence in chronic kidney disease, hypertension and
diabetes.
Questionnaire available from
http://www.clininf.eu/qickd-ccq.html.
Additional files
Additional file 1: Questionnaire: Evaluating Primary Care
Practitioners’ confidence and knowledge in managing chronic
kidney disease.
Additional file 2: Correlation Matrix.
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